Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease.
Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T; ADJUST study group. Tanaka H, et al. Among authors: nojima m. J Gastroenterol Hepatol. 2018 May;33(5):1031-1038. doi: 10.1111/jgh.14034. Epub 2018 Mar 15. J Gastroenterol Hepatol. 2018. PMID: 29087616
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Matsumoto T, et al. Among authors: nojima m. J Crohns Colitis. 2016 Nov;10(11):1259-1266. doi: 10.1093/ecco-jcc/jjw152. Epub 2016 Aug 26. J Crohns Colitis. 2016. PMID: 27566367 Clinical Trial.
Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Nakase H, et al. Among authors: nojima m. Aliment Pharmacol Ther. 2017 Nov;46(9):873-882. doi: 10.1111/apt.14318. Epub 2017 Sep 8. Aliment Pharmacol Ther. 2017. PMID: 28884856 Free PMC article. Clinical Trial.
Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Watanabe K, et al. Among authors: nojima m. Clin Gastroenterol Hepatol. 2018 Apr;16(4):542-549.e1. doi: 10.1016/j.cgh.2017.10.036. Epub 2017 Nov 11. Clin Gastroenterol Hepatol. 2018. PMID: 29104132 Free article. Clinical Trial.
High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y. Shinkai N, et al. Among authors: nojima m. J Gastroenterol. 2018 Jul;53(7):883-889. doi: 10.1007/s00535-017-1424-0. Epub 2017 Dec 29. J Gastroenterol. 2018. PMID: 29288305
Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Hisamatsu T, et al. Among authors: nojima m. J Crohns Colitis. 2019 Sep 19;13(9):1097-1104. doi: 10.1093/ecco-jcc/jjz030. J Crohns Colitis. 2019. PMID: 30753377 Clinical Trial.
468 results